

Efficacy of Quetiapine in Parkinson's Psychosis

Submission date 14/07/2005	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 09/09/2005	Overall study status Completed	☐ Protocol
Last Edited 06/10/2009	Condition category Nervous System Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Anthony David

Contact details

Institute of Psychiatry
P.O. Box 68
De Crespigny Park
Denmark Hill
London
United Kingdom
SE5 8AF
+44 (0)207 848 0138
A.David@iop.kcl.ac.uk

Additional identifiers

Protocol serial number

KCL/KCH-CT2004-1

Study information

Scientific Title

Acronym

EQuiPP

Study objectives

The study hypothesis is that Quetiapine is effective in the treatment of the psychotic symptoms (hallucinations/delusions) seen in Parkinson's disease

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised placebo controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Parkinson's disease

Interventions

Quetiapine versus Placebo

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Quetiapine

Primary outcome(s)

1. Improvement in psychotic symptoms
2. Parkinsonian symptoms
3. Depressive symptoms
4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen)

Key secondary outcome(s)

1. Activities of daily living
2. Cognitive function
3. Carer burden

Completion date

01/08/2006

Eligibility

Key inclusion criteria

1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Anti-psychotic medication in the preceding 3 months
2. Any contra-indication to quetiapine
3. Any important drug interactions
4. Major concomitant medical illness
5. History of uncontrolled diabetes or hypertension
6. Changes in medication in the last 14 days

Date of first enrolment

01/08/2005

Date of final enrolment

01/08/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Institute of Psychiatry

London

United Kingdom

SE5 8AF

Sponsor information

Organisation

King's College London (UK)

ROR

<https://ror.org/0220mzb33>

Funder(s)**Funder type**

Charity

Funder Name

Parkinson's Disease Society (UK) (Ref: 4052)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2009		Yes	No